News

News2019-07-22T02:46:50+00:00

REGiMMUNE Completes $6 Million Series E Financing

Tokyo, Japan – April 7, 2017 – REGiMMUNE Corporation announced the closing of a Series E financing on April 7th. The company raised 6 million US in this new round, which was led by SMBC Venture Capital Co., Ltd., the VC arm of Sumitomo Mitsui Banking Corporation(SMBC) and Japan Asia Investment Corporation (JAIC). Additional investors [...]

May 12th, 2017|

Moving Headquarters Location

We are proud to announce that we have moved our business to a new location. Our new address is as follows. 35-3 Nihonbashi Hakozaki-cho BRICK GATE 5F Chuou-ku Tokyo 103-0015 Japan.Our Telephone numbers remain the same.

December 12th, 2016|

REGiMMUNE Appoints Kenzo Kosuda as Chief Executive Officer

Tokyo Japan — July 1, 2016 — REGiMMMUNE today announced that its Board of Directors has appointed Kenzo Kosuda as Chief Executive Officer effective July 1, 2016. Yasuyuki Ishii will assume the role of Executive Chairman on July 1, 2016, and will continue to serve as the Chairman of REGiMMUNE’s Board. "This is an appropriate [...]

July 1st, 2016|

REGiMMUNE appoints new board members

REGiMMUNE Corporation (RGI) Appointed  Joseph “Joe” McCracken as a board Tokyo, Japan., Dec 25, 2015 – REGiMMUNE Corporation (RGI) today announced that the Company has appointed Joseph McCracken to its Board of Directors. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives, and serves on the [...]

December 25th, 2015|

REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells

REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells – Antigen-Specific Immunotherapy to Potentially Prevent or Delay Diabetes in Preclinical Model – Tokyo, Japan – April 15 – REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer [...]

April 15th, 2015|

Moving Headquarters Location

We are proud to announce that we have moved our business to a new location with a much larger working space. Our new address is as follows. 14-9 Nihonbashi Kodenma-cho Fine Bldg. 7F Chuou-ku Tokyo 103-0001 Japan.Our Telephone numbers remain the same.

June 16th, 2014|

REGiMMUNE Presenting at The 21st Annual the Future Leaders in the Biotech Industry 2014 Tomorrow at 4:00 PM Eastern

Tokyo–REGiMMUNE Corporation (“REGiMMUNE” or “the Company”), a biopharmaceutical Company developing innovative therapeutics for the treatment of immune disorders, is presenting tomorrow at 4:00 pm Eastern. Mr. Haru Morita, President and CEO, will present a corporate update at The 21st Annual the Future Leaders in the Biotech Industry 2014. Presentation Information: Date: Friday, March 28th, 2014 [...]

March 27th, 2014|

REGiMMUNE Presenting at The 21st Annual the Future Leaders in the Biotech Industry 2014 Tomorrow at 4:00 PM Eastern

Tokyo–REGiMMUNE Corporation (“REGiMMUNE” or “the Company”), a biopharmaceutical Company developing innovative therapeutics for the treatment of immune disorders, is presenting tomorrow at 4:00 pm Eastern. Mr. Haru Morita, President and CEO, will present a corporate update at The 21st Annual the Future Leaders in the Biotech Industry 2014. Presentation Information: Date: Friday, March 28th, 2014 [...]

March 27th, 2014|

American Journal of Transplantation Reports REGiMMUNE’s Preclinical Results of its Method for Long-term Tolerance in Organ Transplantation

REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation without continuous administration of immune suppressants. “A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Costimulatory Blockade” was published in the AJT March 2014 Issue 3, Volume 14, [...]

February 28th, 2014|

American Journal of Transplantation Reports REGiMMUNE’s Preclinical Results of its Method for Long-term Tolerance in Organ Transplantation

REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation without continuous administration of immune suppressants. “A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Costimulatory Blockade” was published in the AJT March 2014 Issue 3, Volume 14, [...]

February 28th, 2014|

REGiMMUNE Completes $9.2 Million Series D Financing

Tokyo, Japan – February 14, 2014 – REGiMMUNE Corporation announced the closing of a Series D financing earlier this month. The company raised $9.2 million US in this new round, which was led by Japan Asia Investment Corporation (JAIC) and Nippon Venture Capital Corp (NVCC). Additional investors participating in this round are new investors Mizuho [...]

February 14th, 2014|

REGiMMUNE Completes $9.2 Million Series D Financing

REGiMMUNE Completes $9.2 Million Series D Financing Tokyo, Japan – February 14, 2014 – REGiMMUNE Corporation announced the closing of a Series D financing earlier this month. The company raised $9.2 million US in this new round, which was led by Japan Asia Investment Corporation (JAIC) and Nippon Venture Capital Corp (NVCC). Additional investors participating [...]

February 14th, 2014|

REGiMMUNE Begins Enrollment for Phase II Clinical Trial for Graft versus Host Disease

Positive Phase I Clinical Trial Supports Initiation of Phase II Study in Patients with GvHD – Tokyo, Japan – February 6, 2014 – REGiMMUNE Corporation announced today that it has begun a Phase II study of its proprietary compound RGI-2001 for GvHD associated with hematopoietic stem cell transplantation. The multicenter study is being conducted in [...]

February 7th, 2014|